Danon disease is a rare, multisystem X-linked genetic disorder caused by variants in the LAMP2 gene. In children and young adults, it is defined overwhelmingly by its cardiac effects . What is far less appreciated is that the eye is frequently involved and that the retinal findings can appear before the systemic diagnosis is established.
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Two-year PRISM results show 4D-150 gene therapy sustains wet AMD vision while cutting anti-VEGF injections up to 87%, with reassuring safety.
Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central serous chorioretinopathy (CSCR)
Carl C. Awh, MD, FASRS, presented 2-year data at ASRS 2026 showing 4D-150 gene therapy cut anti-VEGF injection burden in wet AMD, with strong safety through 4 years of follow-up.
PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, is commercially available in Europe.
In a first-in-human Phase 1 trial, a single TH103 injection improved vision and reduced fluid in treatment-naive wet AMD, with roughly a third of patients needing no retreatment through 6 months.
An ophthalmologist shares pearls for clinical practice.
Bausch + Lomb’s EyeGility preloaded enVista IOL inserter streamlines cataract surgery with push-plunger delivery, less handling, faster workflow.
5-year OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained aflibercept expression and no new safety signals, in a high-need population with nAMD.
Real-world data presented at ASRS 2026 show pegcetacoplan slowed photoreceptor and RPE loss in geographic atrophy, with a greater treatment effect in eyes with concurrent neovascular AMD.
A wider partial-total ellipsoid zone gap on OCT predicted faster total EZ loss and geographic atrophy in intermediate AMD—pointing to a biomarker for trial enrichment.
David E. I. Pyott, CBE, MD(Hon), MBA, MA, discusses expanding subspecialty training and internationally recognized credentials in underserved regions.
Presenters highlight clinical insights and lessons from recent trial data and surgical experience
New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year, and treatment gaps are linked to worse long-term vision.
3-year REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of gene mutation, with no treatment-related serious adverse events, per Benjamin Bakall, MD, PhD, at ASRS 2026.
AI-driven OCT analysis shows faricimab reduces diabetic macular edema fluid and thickness more than aflibercept, suggesting eccentric subfields may guide treat-and-extend dosing.
Creators on TikTok and YouTube share real LASIK journeys, bust myths, and help Gen Z and millennials explore modern vision correction options.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Building judgment and adaptability to navigate AI, gene therapy, and constant change.
ARCHER data reveal which GA eyes risk major vision loss: midrange baseline acuity and subfoveal lesions, shaping counseling and future AMD trials.
A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.
A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, including in patients with concurrent neovascular AMD, per Nimesh Patel, MD, at ASRS 2026.
Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.
Inflammasome Therapeutics announced positive phase 2 results achieved by kamuvudine-8 (K8), its investigational drug, for geographic atrophy (GA) and a good safety signal over the 6-month period of evaluation. The company also reported significantly slower GA progression and a visual acuity advantage.
An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen failures by 13% in a retina practice.
Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 dose, outperforming aflibercept 2 mg.
Applying phase 3 LUGANO/LUCIA criteria to the phase 2 DAVIO 2 population showed stable vision and anatomy with the vorolanib insert EYP-1901 in wet AMD, Aleksandra Rachitskaya, MD, FASRS, reported at ASRS 2026.
The multicenter study is evaluating ZOC2017217, a lanosterol-derived investigational eye drop, ahead of a planned phase 3 trial.
Rising star in Ophthalmology, Nicholas Riina, MS, focuses on artificial intelligence and uses robotics training to enhance glaucoma diagnosis.
